Properties (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Medication
|
| gptkbp:activeDuring |
gptkb:Pantoprazole
|
| gptkbp:administrativeDivision |
Once daily
Twice daily for certain conditions |
| gptkbp:availableIn |
Tablet
Injection |
| gptkbp:brand |
gptkb:Protonix
|
| gptkbp:clinicalTrials |
Phase III
Long-term treatment Short-term treatment |
| gptkbp:contraindication |
Hypersensitivity to pantoprazole
|
| gptkbp:date |
2000
|
| gptkbp:dosageForm |
Injectable solution
Delayed-release tablet |
| gptkbp:drugInterdiction |
Warfarin
Digoxin Proton pump inhibitor Methotrexate Atazanavir |
| gptkbp:formulation |
Enteric-coated tablet
Powder for injection |
| gptkbp:gestationPeriod |
Category B
|
| gptkbp:hasFilm |
Kidney disease
Clostridium difficile infection Bone fractures |
| gptkbp:healthcare |
Important for effectiveness
|
| https://www.w3.org/2000/01/rdf-schema#label |
Protonix
|
| gptkbp:impact |
As prescribed by a physician
|
| gptkbp:manufacturer |
Takeda_Pharmaceuticals
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:name |
Essential Medicines
|
| gptkbp:numberOfStudents |
1 hour
|
| gptkbp:nutritionalValue |
Liver
|
| gptkbp:offers |
Varies by region
|
| gptkbp:patentExpiration |
2011
|
| gptkbp:patentType |
Yes
|
| gptkbp:route |
Intravenous
Oral |
| gptkbp:safetyFeatures |
Recommended during long-term use
|
| gptkbp:sideEffect |
Diarrhea
Nausea Vomiting Headache Abdominal pain |
| gptkbp:storage |
Room temperature
|
| gptkbp:type |
Yes
|
| gptkbp:usedFor |
gptkb:Zollinger-Ellison_syndrome
Gastroesophageal reflux disease (GERD) Erosive esophagitis |